New Alzheimer's Drugs Face Scrutiny Over Efficacy and Safety

Cambridge scientists raise concerns about the real-world impact, high costs, and significant side effects of lecanemab and donanemab.

Researchers question whether these drugs can significantly reduce dementia morbidity at scale.
The treatments show small cognitive benefits but come with substantial risks, including brain swelling and bleeding.
High costs and stringent eligibility criteria limit accessibility for most patients.
Regulatory bodies in the UK and Europe remain cautious about approval.
Experts emphasize the need for balanced information to help patients make informed decisions.